Current Position: Home > Key Projects > Anti-epidemic project - Research and development of new coronavirus pneumonia vaccine by GeoVax in U.S.A

  Even after the epidemic, the equipment can still be used for access control and attendance, and the investment is not wasted. Infinite city can also undertake international business. The production cycle of 100 sets is about one month.

  Vaccine is recognized as the most economic and effective means to prevent and control infectious diseases. Vaccination has been a public health measure vigorously advocated and implemented by governments and the World Health Organization. As a Wuhan enterprise in the center of the epidemic and specializing in the development of new vaccines, Wuhan BOWO hopes to actively participate in the development of new coronavirus vaccines with its own advantages, so as to cope with the serious threat of the epidemic to people's health and national economy.

  Through intense and intensive communication during the outbreak, Wuhan BOWO signed a letter of intent with GeoVax labs (OTC: govx), a US listed company, to jointly develop the new coronavirus vaccine. The relevant news received extensive attention from domestic and foreign media, and was included in one of the first six teams in the world to start the research and development of the new coronavirus vaccine. According to the agreement, GeoVax will use its mva-vlp vaccine platform and expertise to design and build candidate vaccines using the coronavirus gene sequence from Wuhan. As a partner of the project, Wuhan BOWO will provide further development support, including testing vaccine effectiveness and production, communication with China's public health and regulatory agencies, carrying out follow-up clinical research after obtaining the license until future large-scale production and sales.


One on one service for appointment experts

1